IRLAB Therapeutics AB

IRLAB discovers and develops a portfolio of transformative therapies targeting all stages of Parkinson’s disease. Mesdopetam (IRL790), under development for the treatment of levodopa-induced dyskinesia, has completed Phase IIb and is being prepared for Phase III. Pirepemat (IRL752) is currently in Phase IIb and is being evaluated for its effect on balance and fall frequency in Parkinson’s disease. The pipeline is driven by IRLAB’s proprietary systems biology-based research platform, the Integrative Screening Process (ISP).

IRLAB is listed on Nasdaq Stockholm under the ticker IRLABA.

Back to investments

More investments

View all investments

Apexify AB

We make the world a cooler place

Enginzyme

Enginzyme has a patented enzyme immobilization technology that would enable biomanufacturing — without living organisms. This revolutionary material works with any enzyme and can be deployed using similar tools and techniques to those used in traditional chemical manufacturing, with lower costs and a much smaller environmental footprint

Millow holding AB

Millow has developed a unique and patented AI powered technology for resource and cost-efficient production of clean label vegan food. By fermenting plants or side-streams together with mycelium, complete and ready-to-cook food products are created in less than 24h with excellent taste, appealing texture, full nutritious profile and bioavailable vitamins.